Trial Number

394-23

Condition

Lymphoma

Participant Age Range

18 years and older

Participant Gender

Any

Enrolling Participants

Yes

Overview

“Phase 1, first-in-human, open-label dose escalation and cohort expansion study of KB-0742 in patients with relapsed or refractory solid tumors or non-Hodgkin lymphoma”

Phase 1, First-in-human, Open-label Dose Escalation and Cohort Expansion Study of KB-0742 in Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma

Part 1: Dose Escalation. The primary objective of Part 1 of this study is to evaluate the safety and tolerability of KB-0742 in participants with relapsed or refractory (R/R) solid tumors or non-Hodgkin lymphoma (NHL).

Part 2: Cohort Expansion. The primary objective of Part 2 of this study is to further evaluate the safety and tolerability of KB-0742 in defined participant cohorts.

Provider

Cancer Institute

Amol H Rao, MD

Hematology-Oncology
Fountain Valley, Laguna Hills
View Profile

Location

Orange Coast Medical Center

18111 Brookhurst Street
Fountain Valley
(714) 378-7000
Location Details

Related Clinical Trials

Click on the category you are interested in.

Cancer Care Orange Coast Medical Center
Name
Enter Trial number from the area just below the marquee.
How would you prefer to be contacted?
How did you hear about us?
This registration is for:
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.